AP2005003343A0 - Substituted pyrrolo-pyrazole derivatives as kinaseinhibitors - Google Patents
Substituted pyrrolo-pyrazole derivatives as kinaseinhibitorsInfo
- Publication number
- AP2005003343A0 AP2005003343A0 AP2005003343A AP2005003343A AP2005003343A0 AP 2005003343 A0 AP2005003343 A0 AP 2005003343A0 AP 2005003343 A AP2005003343 A AP 2005003343A AP 2005003343 A AP2005003343 A AP 2005003343A AP 2005003343 A0 AP2005003343 A0 AP 2005003343A0
- Authority
- AP
- ARIPO
- Prior art keywords
- kinaseinhibitors
- pyrazole derivatives
- substituted pyrrolo
- pyrrolo
- substituted
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- GZTPJDLYPMPRDF-UHFFFAOYSA-N pyrrolo[3,2-c]pyrazole Chemical class N1=NC2=CC=NC2=C1 GZTPJDLYPMPRDF-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43495202P | 2002-12-19 | 2002-12-19 | |
| PCT/EP2003/050942 WO2004056827A2 (en) | 2002-12-19 | 2003-12-04 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2005003343A0 true AP2005003343A0 (en) | 2005-06-30 |
Family
ID=32682128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2005003343A AP2005003343A0 (en) | 2002-12-19 | 2003-12-04 | Substituted pyrrolo-pyrazole derivatives as kinaseinhibitors |
Country Status (34)
| Country | Link |
|---|---|
| US (5) | US7407971B2 (es) |
| EP (2) | EP1575954B1 (es) |
| JP (2) | JP4739761B2 (es) |
| KR (2) | KR101223826B1 (es) |
| CN (1) | CN1726217B (es) |
| AP (1) | AP2005003343A0 (es) |
| AR (1) | AR042525A1 (es) |
| AU (1) | AU2003300255B9 (es) |
| BR (1) | BR0317455A (es) |
| CA (1) | CA2508069C (es) |
| CR (2) | CR7880A (es) |
| CU (1) | CU23550B7 (es) |
| EA (1) | EA010596B1 (es) |
| EC (1) | ECSP055864A (es) |
| ES (2) | ES2605848T3 (es) |
| GE (1) | GEP20084435B (es) |
| HK (1) | HK1086256A1 (es) |
| HR (1) | HRP20050562A2 (es) |
| IL (2) | IL169019A (es) |
| IS (1) | IS7857A (es) |
| MA (1) | MA27569A1 (es) |
| ME (1) | MEP52408A (es) |
| MX (1) | MXPA05006791A (es) |
| MY (1) | MY141196A (es) |
| NO (1) | NO333178B1 (es) |
| NZ (1) | NZ540644A (es) |
| OA (1) | OA13015A (es) |
| PL (1) | PL377285A1 (es) |
| RS (1) | RS20050462A (es) |
| TN (1) | TNSN05163A1 (es) |
| TW (1) | TWI327470B (es) |
| UA (1) | UA81790C2 (es) |
| WO (1) | WO2004056827A2 (es) |
| ZA (1) | ZA200504298B (es) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001287654B2 (en) * | 2000-08-10 | 2006-12-14 | Pfizer Italia S.R.I. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| UA81790C2 (uk) | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Заміщені піролопіразольні похідні як інгібітори кінази |
| WO2004076450A1 (en) | 2003-02-27 | 2004-09-10 | J. Uriach Y Compañia S.A. | Pyrazolopyridine derivates |
| WO2004080457A1 (en) * | 2003-03-11 | 2004-09-23 | Pharmacia Italia S.P.A. | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| WO2005030776A1 (en) | 2003-09-23 | 2005-04-07 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrrole derivatives as protein kinase inhibitors |
| EP1732549A4 (en) * | 2004-03-18 | 2009-11-11 | Brigham & Womens Hospital | METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES |
| WO2005089515A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| WO2005089504A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| WO2005089502A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
| EP1812439B2 (en) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP1828169A2 (en) | 2004-12-07 | 2007-09-05 | Locus Pharmaceuticals, Inc. | Urea inhibitors of map kinases |
| JP2008523072A (ja) | 2004-12-07 | 2008-07-03 | ルーカス ファーマシューティカルズ， インコーポレイテッド | タンパク質キナーゼの阻害剤 |
| EP1838718B1 (en) * | 2005-01-10 | 2011-06-15 | Pfizer Inc. | Pyrrolopyrazoles, potent kinase inhibitors |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| CN101346382B (zh) * | 2005-12-21 | 2011-07-06 | 辉瑞产品公司 | 一种有效的羰基氨基吡咯并吡唑激酶抑制剂 |
| PT1979356E (pt) | 2005-12-21 | 2013-11-21 | Pfizer Prod Inc | Carbonilaminopirrolopirazolos, inibidores potentes de cinase |
| ES2442491T3 (es) | 2006-03-03 | 2014-02-11 | Nerviano Medical Sciences S.R.L. | Biciclopirazoles activos como inhibidores de cinasa |
| US20100120717A1 (en) | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
| US8227472B2 (en) | 2006-10-11 | 2012-07-24 | Nerviano Medical Sciences S.R.L. | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors |
| UA96618C2 (en) * | 2007-02-07 | 2011-11-25 | Пфайзер Инк. | 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors |
| WO2008096260A1 (en) | 2007-02-07 | 2008-08-14 | Pfizer Inc. | 3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors |
| MX2009010951A (es) * | 2007-04-12 | 2009-10-29 | Pfizer | Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)-carbaldehid o como inhibidores de proteina quinasa c. |
| US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
| US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| JP2012508768A (ja) * | 2008-11-13 | 2012-04-12 | リンク・メディスン・コーポレーション | アザキノリノン誘導体及びその使用 |
| US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| WO2013074986A1 (en) | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| CA2927917C (en) | 2013-10-18 | 2022-08-09 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| AU2014337044A1 (en) | 2013-10-18 | 2016-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| CN105377852B (zh) * | 2014-05-23 | 2018-08-28 | 深圳明赛瑞霖药业有限公司 | 自身免疫疾病的治疗 |
| US10131679B2 (en) | 2014-10-31 | 2018-11-20 | Ube Industries, Ltd. | Substituted dihydropyrrolopyrazole compound |
| CA2972239A1 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| EP3273966B1 (en) | 2015-03-27 | 2023-05-03 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| CA2989519C (en) | 2015-06-15 | 2023-09-26 | Ube Industries, Ltd. | Substituted dihydropyrrolopyrazole derivative |
| KR101845931B1 (ko) * | 2015-06-18 | 2018-04-05 | 한국화학연구원 | 헤테로아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 pi3 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물 |
| WO2017044858A2 (en) | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| AU2016355303B2 (en) * | 2015-11-20 | 2021-10-07 | Mingsight Pharmaceuticals, Inc. | Treatment of autoimmune disease |
| JP2019112306A (ja) * | 2016-04-28 | 2019-07-11 | 宇部興産株式会社 | 慢性閉塞性肺疾患の治療または予防のための医薬組成物 |
| JP2019112307A (ja) * | 2016-04-28 | 2019-07-11 | 宇部興産株式会社 | 置換ジヒドロピロロピラゾール化合物および他の乾癬治療薬が組み合わせて投与される医薬組成物 |
| JP2019112305A (ja) * | 2016-04-28 | 2019-07-11 | 宇部興産株式会社 | アトピー性皮膚炎の治療または予防のための医薬組成物 |
| CN107337674B (zh) * | 2016-04-29 | 2019-09-20 | 江苏吉贝尔药业股份有限公司 | 用于dpp-iv抑制剂的四氢吡喃胺衍生物、其药物组合物和制剂以及用途 |
| US20220002303A1 (en) | 2018-11-14 | 2022-01-06 | Ube Industries, Ltd. | Dihydropyrrolopyrazole derivative |
| AU2020319005A1 (en) * | 2019-07-23 | 2021-12-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| CN115073471B (zh) * | 2021-03-11 | 2023-03-21 | 沈阳药科大学 | 吡唑并四氢吡咯类衍生物、其制备方法和在医药上的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3526633A (en) * | 1968-03-06 | 1970-09-01 | American Cyanamid Co | Substituted 2,4,5,6-tetrahydropyrrolo(3,4-c)pyrazoles |
| GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| AP2002002442A0 (en) | 1999-08-12 | 2002-03-31 | Pharmacia Italia Spa | 3(5)-Amino-pyrazole derivatives, process for their preparation and their preparation and their use as antitumor agents. |
| US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| AU2001287654B2 (en) * | 2000-08-10 | 2006-12-14 | Pfizer Italia S.R.I. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| WO2002048114A1 (en) | 2000-11-27 | 2002-06-20 | Pharmacia Italia S.P.A. | Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
| EP1379524A2 (en) * | 2001-01-26 | 2004-01-14 | Pharmacia Italia S.p.A. | Chromane derivatives, process for their preparation and their use as antitumor agents |
| CZ2004359A3 (cs) | 2001-09-26 | 2004-09-15 | Pharmacia Italia S.P.A. | Aminoindazolové deriváty aktivní jako inhibitory kinázy, způsob jejich přípravy a farmaceutické prostředky obsahující tyto deriváty |
| UA81790C2 (uk) | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Заміщені піролопіразольні похідні як інгібітори кінази |
-
2003
- 2003-04-12 UA UAA200507098A patent/UA81790C2/uk unknown
- 2003-12-04 CN CN2003801064477A patent/CN1726217B/zh not_active Expired - Lifetime
- 2003-12-04 AP AP2005003343A patent/AP2005003343A0/xx unknown
- 2003-12-04 KR KR1020057011433A patent/KR101223826B1/ko not_active IP Right Cessation
- 2003-12-04 NZ NZ540644A patent/NZ540644A/en not_active IP Right Cessation
- 2003-12-04 GE GEAP20038905A patent/GEP20084435B/en unknown
- 2003-12-04 RS YUP-2005/0462A patent/RS20050462A/sr unknown
- 2003-12-04 OA OA1200500186A patent/OA13015A/fr unknown
- 2003-12-04 ES ES03799536.2T patent/ES2605848T3/es not_active Expired - Lifetime
- 2003-12-04 US US10/539,145 patent/US7407971B2/en not_active Expired - Lifetime
- 2003-12-04 ES ES10179134.1T patent/ES2635191T3/es not_active Expired - Lifetime
- 2003-12-04 WO PCT/EP2003/050942 patent/WO2004056827A2/en active Application Filing
- 2003-12-04 PL PL377285A patent/PL377285A1/pl unknown
- 2003-12-04 KR KR1020127002938A patent/KR20120038465A/ko not_active Application Discontinuation
- 2003-12-04 BR BR0317455-7A patent/BR0317455A/pt not_active IP Right Cessation
- 2003-12-04 MX MXPA05006791A patent/MXPA05006791A/es active IP Right Grant
- 2003-12-04 JP JP2004561484A patent/JP4739761B2/ja not_active Expired - Fee Related
- 2003-12-04 EP EP03799536.2A patent/EP1575954B1/en not_active Expired - Lifetime
- 2003-12-04 AU AU2003300255A patent/AU2003300255B9/en not_active Ceased
- 2003-12-04 ME MEP-524/08A patent/MEP52408A/xx unknown
- 2003-12-04 CA CA2508069A patent/CA2508069C/en not_active Expired - Fee Related
- 2003-12-04 EA EA200501009A patent/EA010596B1/ru not_active IP Right Cessation
- 2003-12-04 EP EP10179134.1A patent/EP2266987B1/en not_active Expired - Lifetime
- 2003-12-05 MY MYPI20034670A patent/MY141196A/en unknown
- 2003-12-16 TW TW092135527A patent/TWI327470B/zh not_active IP Right Cessation
- 2003-12-18 AR ARP030104702A patent/AR042525A1/es unknown
-
2005
- 2005-05-23 IS IS7857A patent/IS7857A/is unknown
- 2005-05-26 ZA ZA200504298A patent/ZA200504298B/en unknown
- 2005-06-06 IL IL169019A patent/IL169019A/en not_active IP Right Cessation
- 2005-06-09 NO NO20052805A patent/NO333178B1/no not_active IP Right Cessation
- 2005-06-14 CU CU20050117A patent/CU23550B7/es not_active IP Right Cessation
- 2005-06-16 HR HR20050562A patent/HRP20050562A2/hr not_active Application Discontinuation
- 2005-06-17 MA MA28347A patent/MA27569A1/fr unknown
- 2005-06-17 TN TNP2005000163A patent/TNSN05163A1/fr unknown
- 2005-06-17 EC EC2005005864A patent/ECSP055864A/es unknown
- 2005-06-17 CR CR7880A patent/CR7880A/es unknown
-
2006
- 2006-05-26 HK HK06106083.9A patent/HK1086256A1/xx not_active IP Right Cessation
-
2008
- 2008-07-29 US US12/181,772 patent/US8557857B2/en not_active Expired - Fee Related
- 2008-10-16 CR CR10370A patent/CR10370A/es not_active Application Discontinuation
-
2011
- 2011-02-14 JP JP2011028813A patent/JP2011144180A/ja not_active Withdrawn
- 2011-10-06 IL IL215617A patent/IL215617A0/en unknown
-
2012
- 2012-09-13 US US13/614,545 patent/US8557845B2/en not_active Expired - Lifetime
- 2012-09-13 US US13/614,499 patent/US8481585B2/en not_active Expired - Lifetime
-
2013
- 2013-08-27 US US14/010,819 patent/US8785448B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2005003343A0 (en) | Substituted pyrrolo-pyrazole derivatives as kinaseinhibitors | |
| AP1850A (en) | Spiroindolineplperidine derivatives | |
| EG24050A (en) | Heterocylocarboxamide derivatives | |
| HK1077068A1 (en) | Azolidinone-vinyl fused-benzene derivatives | |
| IL166121A0 (en) | Indole-3-sulphur derivatives | |
| EP1522540A4 (en) | AZAARENE DERIVATIVES | |
| PL376475A1 (en) | N-substituted-2-oxodihydropyridine derivatives | |
| IL169905A0 (en) | Novel 2-pyridinecarboxamide derivatives | |
| ZA200500471B (en) | N-biarylmethyl aminocycloalkanecarboxamide derivatives | |
| HK1088326A1 (en) | Piperidine-benzenesulfonamide derivatives | |
| HK1089443A1 (en) | Imidazol-4-yl-ethynyl-pyridine derivatives | |
| GB0317665D0 (en) | Qinazoline derivatives | |
| PL1682493T3 (pl) | Pochodne amidoacetonitrylu | |
| IL175189A0 (en) | N-thiazol-2-yl-benzamide derivatives | |
| PT1706373E (pt) | Derivados de amidoacetonitrilo | |
| AU2003222659A8 (en) | 23-o-substituted 5-o-mycaminosyltylonide derivatives | |
| GB0312368D0 (en) | Novel ureido- and amido-pyrazolone derivatives | |
| EP1531854A4 (en) | O-DERIVATED NOCATHIACIN DERIVATIVES | |
| GB0319793D0 (en) | Pyridinylmorpholine derivatives | |
| GB0213488D0 (en) | 2-Naphthamide derivatives | |
| AU2003243397A8 (en) | Homo-camptothecin derivatives | |
| SI1654253T1 (sl) | Substituirani 3-pirolidin-indolni derivati | |
| GB0219894D0 (en) | Dihydropyridinone derivatives | |
| GB0210512D0 (en) | Tetrahydro-napthalene derivatives | |
| AU2003285777A8 (en) | 3-substituted-4-pyrimidone derivatives |